Biopharmaceutical products are now main players within the pharmaceutical industry. However, many biological and biotech products are inherently labile compared to small molecule APIs and so liquid formulations may not always deliver suitable stability for long shelf life and ease of global distribution. Therefore, the dried state is an attractive option, although the drying process is not without its own challenges. In particular, the stripping of the native water shell from proteins may result in loss of potency and denaturation and so the appropriate choice of lyoprotectant excipients is required.
read more